Teriparatide, Recombinant human PTH (rh PTH [1-34]), which has an identical sequence to the 34 N-terminal amino acids of human PTH.
Osteoporosis is defined by the World Health Organization as a T-score of -2.5. T-score is the value compared to control subjects who are at their peak bone mineral density, while Z-score reflects a value compared to patients matched for age and sex.
Osteoporosis is a condition in which bone mass is low and microarchitectural deterioration of bone tissue occurs, leading to bone fragility and an increased risk of fracture.
Gaols of Osteoporosis therapy is to
– prevent fragility fractures and future fractures in post menopausal and elderly
– stabilise/increase bone mass
– relieve symptoms of fractures and/or skeletal deformities
– improvemobility and functional stability
Goal of osteoporosis management: prevention of the first fracture:
– Women who have 1 vertebral fracture have an 11-fold increased risk of ever having another vertebral fracture.
–Women with 1or more pre-existing vertebral fractures have an 5.1-fold increased risk of another vertebral fracture within the next year.
A. Inhibition of bone resorption = antiresorptips:
3. Estrogen+Progestins (HRT)
4. SERMs (Selective estrogen receptor modlators
B. Stimulators of bone formation = anabolic
2. Parathyroid Hormone rhPTH (134):
C. Mixed mechanism of action:
1. Active vit D metbolites
2. Strontium Ranilate
D. Recommended for all women at risk of Osteoporosis:
– Ca and Vit D
Effect of Teriparatide on Structural Indices : Quantitative analysis-Significant changes in –
– Trabecular bone volume
– Structure model index
– Connectivity density
– Cortical thickness
Patient treated with teriparatide 20µg sc/d
Female, age 65
Duration of therapy: 637 days (approx 21 months)
ÞLumbar Spine: +7.4% (group mean = 9.7 ± 7.4%)
ÞTotal Hip: +5.2% (group mean = 2.6 ± 4.9%)